

IFW

Box 5581



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY DOCKET NO.
10/553,906	Tomas Bergman	71752-81710

26288
ALBIHNS STOCKHOLM AB
BOX 5581, LINNEGATAN 2
SE-114 85 STOCKHOLM, SWEDEN
STOCKHOLM,
SWEDEN



INTERNATIONAL APPLICATION NO.	
PCT/SE04/00628	
I.A. FILING DATE	PRIORITY DATE
04/23/2004	04/24/2003

CONFIRMATION NO. 1877
371 FORMALITIES LETTER
OC000000020298638

Date Mailed: 09/05/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

LAMONT M HUNTER

Telephone: (703) 308-9140 EXT 201

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/553,906	PCT/SE04/00628	71752-81710

FORM PCT/DO/EO/922 (371 Formalities Notice)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/533,906
Applicant : Thomas Bergman et al.
Filed : October 21, 2005

Title : HUMAN ALKALINE SPHINGOMYELINASE
AND USE THEREOF

Docket No. : 41348 Customer No. : 000116

Mail Stop Missing Parts
Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDED LETTER RESPONDING TO THE NOTIFICATION TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:


Please disregard our previous response mailed on October 27, 2006, and replace it with this amended response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, dated September 5, 2006. Enclosed please find an electronic form of the Sequence Listing, which the sequence listing information recorded in computer readable form is identical to the written paper and where applicable, includes no new matter, as required by 37 CFR 1.821 (e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

Please note the different sequences:

SEQ ID NO 1	protein from human intestine
SEQ ID NO 2	nucleotide sequence for protein from human intestine
SEQ ID NO 3	protein from human intestine
SEQ ID NO 4	protein from human intestine
SEQ ID NO 5	nucleotide sequence for protein from human intestine
SEQ ID NO 6	protein from human intestine

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Ronald M. Kachmarik
Name of Attorney


Signature of Attorney

November 1, 2006
Date

Appl. No.: 10/553,906
Response filed November 1, 2006
In response to the Notification to Comply with Requirements for Patent
Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures


SEQ ID NO 7	protein from human intestine
SEQ ID NO 8	protein from human intestine
SEQ ID NO 9	protein from human intestine
SEQ ID NO 10	artificial DNA corresponds to expressed tag
SEQ ID NO 11	artificial DNA corresponds to expressed tag
SEQ ID NO 12	artificial DNA primer
SEQ ID NO 13	artificial DNA primer
SEQ ID NO 14	artificial DNA primer
SEQ ID NO 15	artificial DNA primer
SEQ ID NO 16	human protein
SEQ ID NO 17	artificial DNA primer
SEQ ID NO 18	artificial DNA primer

We have therefore inserted "Human" in figure 223 for the sequences 1-9 and 16, and "Artificial" for the sequences 10-15 and 17-18.

Regarding sequence 5 there is an explanation of "n", which has been corrected from position 905 to position 965. It is clear that the "n" is situated in position 965 from the sequence as such.

If there are any fees required by this communication, please charge such fees to our Deposit Account No.: 16-0820, Order No.: 41348.

Respectfully submitted,
PEARNE & GORDON LLP



Ronald M. Kachmarik, Reg. No. 34512

1801 East 9th Street
Suite 1200
Cleveland, Ohio 44114-3108
216-579-1700
November 1, 2006